Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity

Virology

Volumn 397, Issue 1, 2010, Pages 224-230

  Bunnik, Evelien M ^a   Lobbrecht, Marilie S D ^a   van Nuenen, Ad C ^a   Schuitemaker, Hanneke ^a  

^a SANQUIN RESEARCH   (Netherlands)

Author keywords

Envelope; HIV 1; NAb escape; Replication rate

Indexed keywords

NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; GLYCOSYLATION; HOMOSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; MALE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS REPLICATION;

ADAPTATION, BIOLOGICAL; ANTIBODIES, NEUTRALIZING; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; GLYCOSYLATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 74249089192     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.11.009     Document Type: Article

References (52)

1. Albert J., et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4 (1990) 107-112
2. Arendrup M., et al. Autologous HIV-1 neutralizing antibodies: emergence of neutralization resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 5 (1992) 303-307
3. Bailey J.R., Williams T.M., Siliciano R.F., and Blankson J.N. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 203 (2006) 1357-1369
4. Beaumont T., et al. Reversal of HIV-1 IIIB towards a neutralization resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75 (2001) 2246-2252
5. Boom R., et al. A rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28 (1991) 495-503
6. Brumme Z.L., et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 18 (2004) F1-F9
7. Bunnik E.M., Pisas L., van Nuenen A.C., and Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82 (2008) 7932-7941
8. Cao Y., Qin L., Zhang L., Safrit J.T., and Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332 (1995) 201-208
9. Cecilia D., Kleeberger C.A., Munoz A., Giorgi J.V., and Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J. Infect. Dis. 176 (1999) 1365-1374
10. Chohan B., et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79 (2005) 6528-6531
11. Derdeyn C.A., et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004) 2019-2022
12. Etemad B., et al. HIV-1 V1-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J. Virol. 83 (2009) 9694-9708
13. Euler, Z., et al., in press. Cross-reactive neutralizing humoral immunity does not protect from HIV-1 disease progression. J. Infect. Dis.
14. Friedrich T.C., et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat. Med. 10 (2004) 275-281
15. Gray L., et al. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 337 (2005) 384-398
16. Gray E.S., et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81 (2007) 6187-6196
17. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41 (1999) 95-98
18. Harrer T., et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type-1 infection. AIDS Res. Hum. Retroviruses 12 (1996) 585-592
19. Harrigan P.R., Bloor S., and Larder B.A. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72 (1998) 3773-3778
20. Harrigan P.R., et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J. Infect. Dis. 181 (2000) 912-920
21. Jansson M., et al. Sensitivity to inhibition by β-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc. Natl Acad. Sci U.S.A. 93 (1996) 15382-15387
22. Jansson M., et al. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J. Hum. Virol. 2 (1999) 325-338
23. Jensen M.A., et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77 (2003) 13376-13388
24. Karlsson I., et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J. Virol. 78 (2004) 11807-11815
25. Koning F.A., et al. Decreasing sensitivity to RANTES neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 188 (2003) 864-872
26. Leslie A.J., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10 (2004) 282-289
27. Li B., et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 80 (2006) 5211-5218
28. Li B., et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J. Virol. 81 (2007) 193-201
29. Loh L., Batten C.J., Petravic J., Davenport M.P., and Kent S.J. In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J. Virol. 81 (2007) 5418-5422
30. McKeating J.A., et al. Characterization of HIV-1 neutralization escape mutants. AIDS 3 (1989) 777-784
31. Miller C.J., et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J. Virol. 81 (2007) 5024-5035
32. Moore P.L., et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. e1000598 (2009) 5
33. Piantadosi A., et al. HIV-1 neutralizing antibody breadth is affected by factors early in infection, but does not influence disease progression. J. Virol. 83 (2009) 10269-10274
34. Quakkelaar E.D., et al. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. Virology 363 (2007) 447-453
35. Quakkelaar E.D., et al. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J. Virol. 81 (2007) 8533-8542
36. Repits J., et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol. 86 (2005) 2859-2869
37. Repits J., et al. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 379 (2008) 125-134
38. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4144-4149
39. Rong R., et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5 (2009) e1000594
40. Sagar M., Wu X., Lee S., and Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80 (2006) 9586-9598
41. Sagar M., et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J. Infect. Dis. 199 (2009) 580-589
42. Schuitemaker H., et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66 (1992) 1354-1360
43. Sterjovski J., et al. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4 (2007) 89
44. Tersmette M., et al. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 171 (1989) 149-155
45. Van 't Wout A.B., Schuitemaker H., and Kootstra N.A. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat. Protoc. 3 (2008) 363-370
46. van Opijnen T., and Berkhout B. The host environment drives HIV-1 fitness. Rev. Med. Virol. 15 (2005) 219-233
47. van Opijnen T., et al. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J. Virol. 78 (2004) 3675-3683
48. Von Gegerfelt A., Albert J., Morfeldt-Månson L., Broliden K., and Fenyö E.M. Isolate-specific neutralizing antibodies in patients with progressive HIV-1 related disease. Virology 185 (1991) 162-168
49. Watkins B.A., et al. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J. Virol. 67 (1993) 7493-7500
50. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
51. Zhang Y.J., et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J. Infect. Dis. 176 (1997) 1180-1187
52. Zhang M., et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14 (2004) 1229-1246